Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2020, with a specific reporting date of October 14, 2020. The document serves as a transaction notification under Rule 13a-16 or 15d-16, detailing changes in shareholdings by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively reports on specific share transactions executed by senior executives.
| Instrument | Transaction Price | Exchange | Transaction Date |
|---|---|---|---|
| Ordinary Shares (GBP) | £14.2540 | London Stock Exchange (XLON) | 2020-10-12 |
| American Depositary Shares (USD) | $37.1600 | New York Stock Exchange (XNYS) | 2020-10-12 |
Material Changes
The filing reports an increase in the notional interest of Ordinary Shares and ADSs for multiple executives. These increases resulted from the re-investment of dividends paid to shareholders on October 8, 2020, into the Company's Deferred Annual Bonus Plan. No other material changes to the company's operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a regulatory disclosure of executive share transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were automatic re-investments of dividends into the Deferred Annual Bonus Plan, not open-market purchases or sales by executives.
- Participants: Transactions involved 15 senior executives, including the CEO (Ms E Walmsley), CFO (Mr I Mackay), and Chief Scientific Officer (Dr H Barron).
- Share Prices: Ordinary Shares traded at £14.2540 and ADSs at $37.1600 on the transaction date of October 12, 2020.
- Volume: Individual transaction volumes were relatively small, ranging from 31 to 891 shares/ADSs per executive.